Answers are grounded in this paper and cite their sources.
Investigates a prodrug strategy enhancing cancer therapy in dual payload systems, suggesting improved efficacy.
Bioorthogonal prodrug strategies with dual payload activation are pivotal for combinational therapy, yet they remain very scarce. Herein, we report a prodrug–prodrug strategy for the coactivation of a covalent inhibitor alongside a secondary chemotherapeutic agent, leveraging a tandem retro-Cope and Cope elimination. Notably, the rate constants for the initial retro-Cope elimination can be tuned to over 102 M–1s–1 in certain cases. The proof of concept is firmly established for the coactivation of the EGFR covalent inhibitor osimertinib together with the chemotherapeutics doxorubicin or CA4.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: